Quarter ended on March 31, 2025Data in Crores of INR
Revenue₹ 1.42K-7.32% from last year
Operating profits₹ 391.54-2.31% from last year
Net income₹ 186.54-3.06% from last year
Data is unavailable
Data is unavailable
View detailed balance sheet
Profitability ratios
ROA7.97%
ROE9.26%
ROCE13.63%
EPS46.9%
Net profit margin13.64%
Operating profit margin26.54%
Dividend per share20%
Operational ratios Quick ratio2.85%
Current ratio4.04%
Interest coverage44.23%
Assets turnover0.58%
Debt to equity0.04%
Valuation ratios P/E ratio44.72%
P/B ratio3.41%
Dividend yield0.95%
EV/EBITDA
Gland Pharma Limited is focused on meeting diverse injectables needs with a stable supply of affordable and high quality products. It has established a portfolio of injectable products across various therapeutic areas and delivery systems. It is present in sterile injectables, oncology and ophthalmics, and focus on complex injectables, NCE-1s, First-to-File products and 505(b)(2) filings. Its delivery systems include liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags and drops. It is expanding its development and manufacturing capabilities in complex injectables such as peptides, long-acting injectables, suspensions and hormonal products as well as new delivery systems such as pens and cartridges.
Show figures in :
